"We hope that this particular product will make bone marrow transplantation a more widely used and safer option for critically ill patients who undergo chemotherapy to potentially cure blood cancer."This product has the potential to be the first of our revenue generating biologic therapies in both the United States and Europe," Professor Itescu added.
Mesoblast Receives FDA Clearance For Phase 3 Bone Marrow Transplant Trial
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.